NCT07279584尚未招募2 期
An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Golidocitinib Combined With GemOx in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 31
- 主要终点
- Overall Response Rate
研究概览
简要总结
The objective of this study is to evaluate the efficacy and safety of golidocitinib in combination with the GemOx regimen in r/r PTCL
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •fully understood and voluntarily signed the ICF for this study
- •aged ≥ 18 years;
- •patients with R/R PTCL who have received at least one prior systemic therapy.
- •Patients must have at least one measurable lesion by computed tomography (CT)/magnetic resonance imaging (MRI) (longest diameter of lymph node lesions > 1.5 cm or longest diameter of extranodal lesions > 1 cm); evaluable lesions: PET-CT examination showed increased local uptake in lymph nodes or extranodal sites (higher than liver) and imaging characteristics consistent with lymphoma performance
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;
- •Adequate bone marrow function, renal function, liver function: ANC ≥ 1.0 × 109/L, hemoglobin ≥ 8.0 g/dL, platelets ≥ 75 × 109/L Note: if the investigator believes that the patient 's above test values are below the lower limit of the protocol due to lymphoma invading the bone marrow, the patient can be enrolled after assessment.Creatinine clearance > 40 mL/min, calculated by Cockcroft-Gault method: • serum total bilirubin ≤ 1.5 x upper limit of normal (ULN), except for unconjugated bilirubinemia in Gilbert 's syndrome; • ALP (in the absence of bone disease), ALT, and AST ≤ 3.0 × ULN (in the presence of liver metastases, ≤ 5 × ULN); • international normalized ratio (INR) ≤ 1.5 × ULN, or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
- •Current negative for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or cytomegalovirus (CMV), and inactive if positive:
- •HBV infected patients with positive hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (HbcAb)] but negative results of HBV DNA polymerase chain reaction (PCR) test can be enrolled; these patients require continuous antiviral therapy after enrollment and HBV DNA PCR test is performed every cycle;
- •Patients with positive HCV serology but negative HCV RNA test may be enrolled;
- •CMV IgM antibody positive,However, patients who tested negative for CMV DNA could be enrolled;
- •female patients of childbearing potential had to agree to use a double contraception method at least 28 days before starting study drug, during treatment, and for 6 months after the last dose of study drug, and male patients with partners of childbearing potential had to also use an effective double contraception method during the study and for 3 months after the last dose of study drug, e.g., condom, sponge plug, foam, contraceptive jelly, diaphragm cap or intrauterine contraceptive device, contraceptive pills (oral or parenteral), contraceptive implant (Implanon ®), injectable intravascular injection, or other contraceptive measures.Postmenopausal women (> 45 years of age and amenorrheic for > 1 year) and surgically sterile women are exempt from this criterion.
排除标准
- •Patients who meet any of the following exclusion criteria must be excluded from this study:
- •previously used drugs in the treatment regimen may affect the efficacy evaluation of this study (assessed by the investigator)
- •previous bone marrow malignancies, including MDS, AML, MPN, etc.
- •and have clinically significant abnormal test results as judged by the investigator;
- •inability to be orally administered, previous surgical history or severe gastrointestinal diseases such as dysphagia, active gastric ulcer, etc., which the investigator believes may affect the absorption of the study drug;
- •major surgery within 4 weeks before the first study drug administration (referring to grade 3 and 4 surgery as specified in the Measures for the Administration of Clinical Application of Medical Technology implemented on May 1, 2009);
- •current clinically significant active cardiovascular disease, such as uncontrolled arrhythmia, congestive heart failure, any grade 3 or 4 heart disease defined by the New York Heart Association functional classification, or a history of myocardial infarction within 6 months after screening.Left ventricular ejection fraction < 50% measured by echocardiography
- •Venous thrombosis or pulmonary embolism within 3 months before study drug administration;
- •History of stroke or intracranial hemorrhage within 6 months before the first study drug administration;
- •Active infection requiring systemic treatment;
- •History of inflammatory bowel disease (eg, Crohn 's disease or ulcerative colitis);
- •Known hypersensitivity to study drug;
- •Any other disease, metabolic abnormality, physical examination abnormality, or laboratory abnormality of significant clinical significance that, in the judgment of the investigator, gives reason to suspect that the patient has a disease or condition that would make the use of the study drug inappropriate or would compromise the interpretation of the study results or put the patient at high risk.
- •pregnant (positive pregnancy test) or lactating women;
- •patients who have had previous organ transplantation;
- •diagnosed or treated for malignancies other than PTCL, with the following exceptions: a) malignancies treated with curative therapy ≥ 3 years before randomization and without known active disease; b) adequately treated non-melanoma skin cancer or malignancies without evidence of disease
研究组 & 干预措施
Golidocitinib Combined with GemOx
Experimental
干预措施: golidocitinib (Drug)
Golidocitinib Combined with GemOx
Experimental
干预措施: GEMOX (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: Tumor evaluation was assessed at screening and at the end of treatment (around 3 cycles) then every 12-24 weeks until disease progression (each cycle is 21 days) through study completion, an average of 1 year.
Percentage of participants with complete response partial response was determined on the basis of investigator assessments according to 2014 Lugano criteria.
次要结局
- Progression-free survival(Baseline up to data cut-off(up to approximately 2 years))
- Complete Response Rate(Tumor evaluation was assessed at screening and at the end of treatment (around 3 cycles) then every 12-24 weeks until disease progression (each cycle is 21 days) through study completion, an average of 1 year.)
- Duration of Response(Baseline up to data cut-off(up to approximately 2 years))
- Overall survival(Baseline up to data cut-off(up to approximately 2 years))
- Adverse Events(Baseline up to data cut-off(up to approximately 3 years))
研究者
Zhao Weili
Professor and Director，Shanghai Institute of Hematology
Ruijin Hospital
相似试验
尚未招募
1 期
Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell LymphomaNCT07269639Seoul National University Hospital20
招募中
1 期
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaNCT07093710Sun Yat-sen University101
招募中
2 期
A multicenter, open label, two cohort, single arm, phase II study to evaluate the efficacy and safety of the anti-TROP2 antibody-drug conjugate sacituzumab govitecan in patients with advanced differentiated and anaplastic thyroid neoplasms.2023-504898-20-00Grupo Espanol De Tumores Neuroendocrinos42
尚未招募
3 期
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast CancerBreast Cancer2024-513540-29-00Alliance Foundation Trials LLC303
招募中
1 期
Golidocitinib Plus CHOP in Newly Diagnosed PTCLPeripheral T-cell LymphomaNCT06739265Peking Union Medical College Hospital68